Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Diseases
NCT06373081Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-CD19-CD3E-CAR-T cells in systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis (SSc) and 3 more, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Proportion of Patients with Successful Manufacturing at 21 days and 6 more. Started Apr 2024; status: recruiting.
02
Drugs
anti-CD19-CD3E-CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06373081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373081.